14
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Smooth muscle cell recruitment to lymphatic vessels requires PDGFB and impacts vessel size but not identity

      research-article

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Tissue fluid drains through blind-ended lymphatic capillaries, via smooth muscle cell (SMC)-covered collecting vessels into venous circulation. Both defective SMC recruitment to collecting vessels and ectopic recruitment to lymphatic capillaries are thought to contribute to vessel failure, leading to lymphedema. However, mechanisms controlling lymphatic SMC recruitment and its role in vessel maturation are unknown. Here, we demonstrate that platelet-derived growth factor B (PDGFB) regulates lymphatic SMC recruitment in multiple vascular beds. PDGFB is selectively expressed by lymphatic endothelial cells (LECs) of collecting vessels. LEC-specific deletion of Pdgfb prevented SMC recruitment causing dilation and failure of pulsatile contraction of collecting vessels. However, vessel remodelling and identity were unaffected. Unexpectedly, Pdgfb overexpression in LECs did not induce SMC recruitment to capillaries. This was explained by the demonstrated requirement of PDGFB extracellular matrix (ECM) retention for lymphatic SMC recruitment, and the low presence of PDGFB-binding ECM components around lymphatic capillaries. These results demonstrate the requirement of LEC-autonomous PDGFB expression and retention for SMC recruitment to lymphatic vessels, and suggest an ECM-controlled checkpoint that prevents SMC investment of capillaries, which is a common feature in lymphedematous skin.

          Abstract

          Summary: Pdgfb mutant mice provide insight into the recruitment and function of smooth muscle cells in the lymphatic vasculature, and shed new light on mechanisms of lymph vessel-associated diseases.

          Related collections

          Most cited references19

          • Record: found
          • Abstract: found
          • Article: not found

          A model for gene therapy of human hereditary lymphedema.

          Primary human lymphedema (Milroy's disease), characterized by a chronic and disfiguring swelling of the extremities, is associated with heterozygous inactivating missense mutations of the gene encoding vascular endothelial growth factor C/D receptor (VEGFR-3). Here, we describe a mouse model and a possible treatment for primary lymphedema. Like the human patients, the lymphedema (Chy) mice have an inactivating Vegfr3 mutation in their germ line, and swelling of the limbs because of hypoplastic cutaneous, but not visceral, lymphatic vessels. Neuropilin (NRP)-2 bound VEGF-C and was expressed in the visceral, but not in the cutaneous, lymphatic endothelia, suggesting that it may participate in the pathogenesis of lymphedema. By using virus-mediated VEGF-C gene therapy, we were able to generate functional lymphatic vessels in the lymphedema mice. Our results suggest that growth factor gene therapy is applicable to human lymphedema and provide a paradigm for other diseases associated with mutant receptors.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            FOXC2 and fluid shear stress stabilize postnatal lymphatic vasculature.

            Biomechanical forces, such as fluid shear stress, govern multiple aspects of endothelial cell biology. In blood vessels, disturbed flow is associated with vascular diseases, such as atherosclerosis, and promotes endothelial cell proliferation and apoptosis. Here, we identified an important role for disturbed flow in lymphatic vessels, in which it cooperates with the transcription factor FOXC2 to ensure lifelong stability of the lymphatic vasculature. In cultured lymphatic endothelial cells, FOXC2 inactivation conferred abnormal shear stress sensing, promoting junction disassembly and entry into the cell cycle. Loss of FOXC2-dependent quiescence was mediated by the Hippo pathway transcriptional coactivator TAZ and, ultimately, led to cell death. In murine models, inducible deletion of Foxc2 within the lymphatic vasculature led to cell-cell junction defects, regression of valves, and focal vascular lumen collapse, which triggered generalized lymphatic vascular dysfunction and lethality. Together, our work describes a fundamental mechanism by which FOXC2 and oscillatory shear stress maintain lymphatic endothelial cell quiescence through intercellular junction and cytoskeleton stabilization and provides an essential link between biomechanical forces and endothelial cell identity that is necessary for postnatal vessel homeostasis. As FOXC2 is mutated in lymphedema-distichiasis syndrome, our data also underscore the role of impaired mechanotransduction in the pathology of this hereditary human disease.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              FOXC2 controls formation and maturation of lymphatic collecting vessels through cooperation with NFATc1

              The mechanisms of blood vessel maturation into distinct parts of the blood vasculature such as arteries, veins, and capillaries have been the subject of intense investigation over recent years. In contrast, our knowledge of lymphatic vessel maturation is still fragmentary. In this study, we provide a molecular and morphological characterization of the major steps in the maturation of the primary lymphatic capillary plexus into collecting lymphatic vessels during development and show that forkhead transcription factor Foxc2 controls this process. We further identify transcription factor NFATc1 as a novel regulator of lymphatic development and describe a previously unsuspected link between NFATc1 and Foxc2 in the regulation of lymphatic maturation. We also provide a genome-wide map of FOXC2-binding sites in lymphatic endothelial cells, identify a novel consensus FOXC2 sequence, and show that NFATc1 physically interacts with FOXC2-binding enhancers. As damage to collecting vessels is a major cause of lymphatic dysfunction in humans, our results suggest that FOXC2 and NFATc1 are potential targets for therapeutic intervention.
                Bookmark

                Author and article information

                Journal
                Development
                Development
                DEV
                develop
                Development (Cambridge, England)
                The Company of Biologists Ltd
                0950-1991
                1477-9129
                1 October 2017
                1 October 2017
                : 144
                : 19
                : 3590-3601
                Affiliations
                [1 ]Karolinska Institutet , Department of Medical Biochemistry and Biophysics, Division of Vascular Biology, Scheeles Väg 2, SE171 77 Stockholm, Sweden
                [2 ]Uppsala University , Dept. Immunology, Genetics and Pathology, Rudbeck Laboratory, Dag Hammarskjölds väg 20, SE751 85 Uppsala, Sweden
                [3 ]Integrated Cardio Metabolic Centre (ICMC), Karolinska Institutet , Novum, Blickagången 6, SE14157 Huddinge, Sweden
                Author notes
                [*]

                These authors contributed equally to this work

                []Authors for correspondence ( taija.makinen@ 123456igp.uu.se ; lars.jakobsson@ 123456ki.se )
                Author information
                http://orcid.org/0000-0001-7956-587X
                Article
                DEV147967
                10.1242/dev.147967
                5665477
                28851707
                19a6837b-bb3d-4148-a186-2e2d02520478
                © 2017. Published by The Company of Biologists Ltd

                This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.

                History
                : 10 December 2016
                : 21 August 2017
                Funding
                Funded by: William K. Bowes, Jr. Foundation, http://dx.doi.org/10.13039/100010246;
                Funded by: Vetenskapsrådet, http://dx.doi.org/10.13039/501100004359;
                Award ID: 521-2011-3044 2015-00550
                Award ID: 542-2014-3535
                Funded by: Cancerfonden, http://dx.doi.org/10.13039/501100002794;
                Award ID: CAN 2014/855 CAN 2015/0735
                Funded by: Karolinska Institutet, http://dx.doi.org/10.13039/501100004047;
                Funded by: Jeanssons Stiftelser, http://dx.doi.org/10.13039/100008738;
                Funded by: Magnus Bergvalls Stiftelse, http://dx.doi.org/10.13039/501100006285;
                Funded by: Knut och Alice Wallenbergs Stiftelse, http://dx.doi.org/10.13039/501100004063;
                Award ID: 2015.0030
                Funded by: European Research Council, http://dx.doi.org/10.13039/100010663;
                Award ID: ERC-2014-CoG-646849 AdG 294556 Bbbarrier
                Funded by: Foundation Leducq;
                Categories
                Research Article

                Developmental biology
                lymphatic vasculature,pdgfb,contraction,lymphedema,morphogenesis,smooth muscle cell

                Comments

                Comment on this article